Please ensure Javascript is enabled for purposes of website accessibility
Home / Products / Antibody / Recombinant Antibody

Anti-Human EGFL6 Antibody (SAA1861)

Catalog #:   RHN02601 Specific References (30) DATASHEET
Host species: Mouse
Isotype: IgG2a, kappa
Applications: ELISA
Accession: Q8IUX8
Overview

Catalog No.

RHN02601

Species reactivity

Human

Host species

Mouse

Isotype

IgG2a, kappa

Clonality

Monoclonal

Target

EGF-like protein 6, Epidermal growth factor-like protein 6, MAEG, MAM and EGF domains-containing gene protein, EGFL6

Concentration

1 mg/ml

Endotoxin level

Please contact with the lab for this information.

Purity

>95% as determined by SDS-PAGE.

Purification

Protein A/G purified from cell culture supernatant.

Accession

Q8IUX8

Applications

ELISA

Form

Liquid

Storage buffer

0.01M PBS, pH 7.4.

Stability and Storage

Use a manual defrost freezer and avoid repeated freeze-thaw cycles. Store at 4°C short term (1-2 weeks). Store at -20°C 12 months. Store at -80°C long term.

Clone ID

SAA1861

Data Image
References

A phase I study of temsirolimus in combination with metformin in patients with advanced or recurrent endometrial cancer., PMID:39787747

UBA1 inhibition sensitizes cancer cells to PARP inhibitors., PMID:39626673

Egfl6 promotes ovarian cancer progression by enhancing the immunosuppressive functions of tumor-associated myeloid cells., PMID:39312740

Results of a randomized phase II trial of paclitaxel and carboplatin versus bleomycin, etoposide and cisplatin for newly diagnosed and recurrent Chemonaive stromal ovarian tumors: An NRG oncology/gynecologic oncology group study14., PMID:39265466

Targeting ONECUT2 inhibits tumor angiogenesis via down-regulating ZKSCAN3/VEGFA., PMID:38797268

Phase I and Randomized Phase II Study of Ruxolitinib With Frontline Neoadjuvant Therapy in Advanced Ovarian Cancer: An NRG Oncology Group Study., PMID:38776484

Angiogenesis-Enabled Human Ovarian Tumor Microenvironment-Chip Evaluates Pathophysiology of Platelets in Microcirculation., PMID:38553940

Phase 1b study of intraperitoneal ipilimumab and nivolumab in patients with recurrent gynecologic malignancies with peritoneal carcinomatosis., PMID:38471508

PRMT blockade induces defective DNA replication stress response and synergizes with PARP inhibition., PMID:38118413

The biology of hope: Inflammatory and neuroendocrine profiles in ovarian cancer patients., PMID:38081436

Randomized phase 2 trial of tremelimumab and durvalumab in combination versus sequentially in recurrent platinum-resistant ovarian cancer., PMID:38009662

Widespread BRCA1/2-independent homologous recombination defects are caused by alterations in RNA-binding proteins., PMID:37909041

Low-grade serous ovarian cancer: expert consensus report on the state of the science., PMID:37591609

Uptake and Outcomes of Neoadjuvant Chemotherapy Among US Patients With Less Common Epithelial Ovarian Carcinomas., PMID:37326992

A Phase I Trial of Bevacizumab and Temsirolimus in Combination With Valproic Acid in Advanced Solid Tumors., PMID:37311055

Secondary Cytoreductive Surgery With Hyperthermic Intraperitoneal Chemotherapy for Advanced or Recurrent Mucinous Ovarian Cancer., PMID:37023452

Clinical implications of tumor-based next-generation sequencing in high-grade epithelial ovarian cancer., PMID:36930815

Generation and characterization of humanized affinity-matured EGFL6 antibodies for ovarian cancer therapy., PMID:36804621

Antibody therapeutics for epithelial ovarian cancer., PMID:36302510

Classification of High-Grade Serous Ovarian Cancer Using Tumor Morphologic Characteristics., PMID:36239936

Race-associated molecular changes in gynecologic malignancies., PMID:35992327

Epidermal growth factor-like domain protein 6 recombinant protein facilitates osteogenic differentiation in adipose stem cells via bone morphogenetic protein 2/recombinant mothers against decapentaplegic homolog 4 signaling pathway., PMID:35220882

EGFL6 promotes colorectal cancer cell growth and mobility and the anti-cancer property of anti-EGFL6 antibody., PMID:33726836

Knockout of EGFL6 by CRISPR/Cas9 Mediated Inhibition of Tumor Angiogenesis in Ovarian Cancer., PMID:32983976

The emerging role of EGFL6 in angiogenesis and tumor progression., PMID:32624687

miR-6086 inhibits ovarian cancer angiogenesis by downregulating the OC2/VEGFA/EGFL6 axis., PMID:32393810

Small RNA Sequencing across Diverse Biofluids Identifies Optimal Methods for exRNA Isolation., PMID:30951671

EGFL6 promotes breast cancer by simultaneously enhancing cancer cell metastasis and stimulating tumor angiogenesis., PMID:30455428

EGFL6 Regulates the Asymmetric Division, Maintenance, and Metastasis of ALDH+ Ovarian Cancer Cells., PMID:27803106

Tumor vascular proteins as biomarkers in ovarian cancer., PMID:17327606

Datasheet
$ 328
Product specifications
100 μg 328 1 mg 1640

Contact Information

Order: order@antibodysystem.com

Mail: support@antibodysystem.com

Distributor list

For research use only. Not for human or drug use.

Need help with your order?

Find out more about placing an order here

Anti-Human EGFL6 Antibody (SAA1861) [RHN02601]
Terms of sale Website terms of use Cookie policy Privacy
Copyright © 2025 AntibodySystem SAS. All Rights Reserved.            All Products are for Research Use Only